• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Xa 因子和凝血酶的多效性效应:新型抗凝剂的预期效果。

Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants.

机构信息

Laboratory for Clinical Thrombosis and Haemostasis, Department of Internal Medicine, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, PO Box 616, UNS50 Box 8, 6200 MD Maastricht, The Netherlands.

出版信息

Cardiovasc Res. 2014 Mar 1;101(3):344-51. doi: 10.1093/cvr/cvt343. Epub 2014 Jan 2.

DOI:10.1093/cvr/cvt343
PMID:24385341
Abstract

Factor Xa and thrombin are well-known components of the coagulation cascade and have been proven to be viable targets for effective anticoagulation treatment. However, accumulating evidence suggests that these serine proteases are also crucial modulators of other cellular mechanisms through the activation of protease-activated receptor (PAR)-mediated signalling. The involvement of factor Xa, thrombin, and PARs in normal biological and pathophysiological processes has been recognized, and their potential implications have been explored in recent years. Both factor Xa and thrombin play significant roles in mediating cellular signalling effects associated with the initial development of atherosclerosis: a chronic inflammatory vascular disease. In addition, increased expression and activation of PARs may be associated with atrial fibrillation (AF) and AF-associated thromboembolism hypercoagulability. Both pathologies are associated with hypercoagulability, suggesting that the role of cellular effects of factor Xa and thrombin and of their specific inhibitors should be studied in relation to the prevention of thrombotic and pro-arrhythmic changes. This review examines the role of factor Xa-mediated and thrombin-mediated PAR activation in modulating cellular processes involved in atherosclerosis and AF and discusses the potential implication of direct factor Xa and thrombin inhibition on effects outside coagulation.

摘要

Xa 因子和凝血酶是凝血级联反应中众所周知的组成部分,已被证明是有效抗凝治疗的可行靶点。然而,越来越多的证据表明,这些丝氨酸蛋白酶也是其他细胞机制的关键调节剂,通过激活蛋白酶激活受体 (PAR) 介导的信号转导。Xa 因子、凝血酶和 PARs 参与正常的生物学和病理生理学过程已得到认可,近年来它们的潜在意义也得到了探讨。Xa 因子和凝血酶都在介导与动脉粥样硬化初始发展相关的细胞信号效应中发挥重要作用:一种慢性炎症性血管疾病。此外,PAR 的表达和激活增加可能与心房颤动 (AF) 和 AF 相关的血栓栓塞性高凝状态有关。这两种病理都与高凝状态有关,这表明应该研究 Xa 因子和凝血酶及其特定抑制剂的细胞作用,以预防血栓形成和致心律失常变化。这篇综述检查了 Xa 因子介导和凝血酶介导的 PAR 激活在调节参与动脉粥样硬化和 AF 的细胞过程中的作用,并讨论了直接抑制 Xa 因子和凝血酶对凝血以外的作用的潜在意义。

相似文献

1
Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants.Xa 因子和凝血酶的多效性效应:新型抗凝剂的预期效果。
Cardiovasc Res. 2014 Mar 1;101(3):344-51. doi: 10.1093/cvr/cvt343. Epub 2014 Jan 2.
2
Targeting factor Xa and thrombin: impact on coagulation and beyond.靶向因子Xa和凝血酶:对凝血及其他方面的影响。
Thromb Haemost. 2014 Apr 1;111(4):625-33. doi: 10.1160/TH13-09-0730. Epub 2013 Dec 12.
3
Nonhemostatic Activities of Factor Xa: Are There Pleiotropic Effects of Anti-FXa Direct Oral Anticoagulants?Xa 因子的非止血活性:抗 Xa 直接口服抗凝剂是否具有多效性作用?
Angiology. 2019 Nov;70(10):896-907. doi: 10.1177/0003319719840861. Epub 2019 Apr 22.
4
Blood coagulation factor Xa as an emerging drug target.凝血因子 Xa 作为一个新兴的药物靶点。
Expert Opin Ther Targets. 2011 Mar;15(3):341-9. doi: 10.1517/14728222.2011.553608. Epub 2011 Jan 21.
5
New oral anticoagulants in atrial fibrillation.心房颤动的新型口服抗凝药。
Eur Heart J. 2008 Jan;29(2):155-65. doi: 10.1093/eurheartj/ehm575. Epub 2007 Dec 19.
6
The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants.利伐沙班(一种口服、直接的 Xa 因子抑制剂)的作用机制与其他抗凝剂的比较。
Thromb Res. 2011 Jun;127(6):497-504. doi: 10.1016/j.thromres.2010.09.008. Epub 2010 Oct 2.
7
The new era of anticoagulation.抗凝治疗的新时代。
Ann Vasc Surg. 2014 Feb;28(2):503-14. doi: 10.1016/j.avsg.2013.07.013. Epub 2013 Oct 1.
8
Differential cellular effects of old and new oral anticoagulants: consequences to the genesis and progression of atherosclerosis.新型与传统口服抗凝剂的细胞效应差异:对动脉粥样硬化发生与进展的影响
Thromb Haemost. 2014 Nov;112(5):909-17. doi: 10.1160/TH14-03-0268. Epub 2014 Oct 9.
9
Straight to the heart: Pleiotropic antiarrhythmic actions of oral anticoagulants.直击要害:口服抗凝剂的多效抗心律失常作用。
Pharmacol Res. 2019 Jul;145:104257. doi: 10.1016/j.phrs.2019.104257. Epub 2019 May 2.
10
Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices.心房颤动中的卒中:病理生理学、新型抗栓治疗以及手术和器械进展的最新情况
Ann Med. 2007;39(5):371-91. doi: 10.1080/07853890701320662.

引用本文的文献

1
Efficacy and Safety of Low-Dose Rivaroxaban in High-Ischemic-Risk Patients with Chronic Coronary Syndrome: Rationale and Design of the DUTCH CCS Registry.低剂量利伐沙班在慢性冠状动脉综合征高缺血风险患者中的疗效和安全性:荷兰CCS注册研究的原理与设计
J Clin Med. 2025 Jun 20;14(13):4401. doi: 10.3390/jcm14134401.
2
Dexmedetomidine Reduces Chronic Stress-Related Thrombosis in a Mouse FeCl Model.右美托咪定可减轻小鼠FeCl模型中与慢性应激相关的血栓形成。
FASEB J. 2025 May 15;39(9):e70546. doi: 10.1096/fj.202500724R.
3
Rivaroxaban as a Protector of Oxidative Stress-Induced Vascular Endothelial Glycocalyx Damage via the IQGAP1/PAR1-2/PI3K/Akt Pathway.
利伐沙班通过IQGAP1/PAR1-2/PI3K/Akt途径作为氧化应激诱导的血管内皮糖萼损伤的保护剂。
J Vasc Res. 2025;62(1):22-36. doi: 10.1159/000542419. Epub 2024 Nov 2.
4
Translation of pathophysiological mechanisms of atrial fibrosis into new diagnostic and therapeutic approaches.心房纤维化病理生理机制向新诊断和治疗方法的转化。
Nat Rev Cardiol. 2025 Apr;22(4):225-240. doi: 10.1038/s41569-024-01088-w. Epub 2024 Oct 23.
5
Inhibitory effect of rivaroxaban on protease-activated receptor-2 in circulating neutrophils among patients with atrial fibrillation.利伐沙班对心房颤动患者循环中性粒细胞中蛋白酶激活受体-2的抑制作用。
Int J Cardiol Heart Vasc. 2024 Mar 20;52:101387. doi: 10.1016/j.ijcha.2024.101387. eCollection 2024 Jun.
6
Characterization of Biomarkers of Thrombo-Inflammation in Patients with First-Diagnosed Atrial Fibrillation.首次诊断为心房颤动患者的血栓炎症生物标志物特征。
Int J Mol Sci. 2024 Apr 8;25(7):4109. doi: 10.3390/ijms25074109.
7
Prognostic Value of Antithrombin Activity Levels in the Early Phase of Intensive Care: A 2-Center Retrospective Cohort Study.重症监护早期抗凝血酶活性水平的预后价值:一项 2 中心回顾性队列研究。
Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231218711. doi: 10.1177/10760296231218711.
8
Dual-Pathway Inhibition with Rivaroxaban and Low-Dose Aspirin Does Not Alter Immune Cell Responsiveness and Distribution in Patients with Coronary Artery Disease.利伐沙班与小剂量阿司匹林双途径抑制不会改变冠心病患者的免疫细胞反应性和分布。
Cardiol Ther. 2024 Mar;13(1):233-242. doi: 10.1007/s40119-023-00342-5. Epub 2023 Dec 6.
9
Distinct pleiotropic effects of direct oral anticoagulants on cultured endothelial cells: a comprehensive review.直接口服抗凝剂对培养内皮细胞的不同多效性作用:一项全面综述
Front Pharmacol. 2023 Sep 29;14:1244098. doi: 10.3389/fphar.2023.1244098. eCollection 2023.
10
Rivaroxaban attenuates neutrophil maturation in the bone marrow niche.利伐沙班可减弱骨髓龛中中性粒细胞的成熟。
Basic Res Cardiol. 2023 Aug 14;118(1):31. doi: 10.1007/s00395-023-01001-5.